Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 5, 2024
Dynamic changes of gut microbiota in mouse models of metabolic dysfunction-associated steatohepatitis and its transition to hepatocellular carcinomaYu-Li Wang, Chang Liu, Yong-Yu Yang, et al.
Theranostics|August 31, 2023
Secretome of senescent hepatic stellate cells favors malignant transformation from nonalcoholic steatohepatitis-fibrotic progression to hepatocellular carcinomaYuan Zhou, Li Zhang, Yue Ma, et al.
European Journal of Medical Research|January 6, 2026
Proliferation, migration, and differentiation of circulating ILC precursors in HBV infection-associated fibrosisQin Zhu, Fang-Yuan Chen, Shi-Qin Li, et al.
Clinical and Translational Medicine|March 21, 2024
JCAD deficiency delayed liver regenerative repair through the Hippo-YAP signalling pathwayLi Zhang, Yong-Yu Yang, Li Xie, et al.
Environmental Science and Pollution Research International|June 4, 2023
Polydopamine-modification of a magnetic composite constructed from citric acid-cross-linked cyclodextrin and graphene oxide for dye removal from watersQing-Di Hu, Hong-Liu Jiang, Kwok-Ho Lam, et al.
Clinical and Molecular Hepatology|January 8, 2024
JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosisLi Xie, Hui Chen, Li Zhang, et al.
Cancer Letters|March 7, 2024
TGF-β1/SMAD3-driven GLI2 isoform expression contributes to aggressive phenotypes of hepatocellular carcinomaJia Ding, Yong-Yu Yang, Peng-Tao Li, et al.
Hepatology (Baltimore, Md.)|May 20, 2025
Suppressing MASH fibrotic progression by blocking succinate-GPR91 signaling in hepatic stellate cellsLi Xie, Hui Chen, Li Zhang, et al.
Hepatology (Baltimore, Md.)|February 5, 2025
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stagesDa-Long Yang, Lin Ye, Fan-Jian Zeng, et al.
Liver Cancer|June 11, 2025
Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter StudyDa-Long Yang, Ning Peng, Jun-Liang Nong, et al.
Pageof 4